Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas.
| Revenue (Most Recent Fiscal Year) | $0.11M |
| Net Income (Most Recent Fiscal Year) | $-4.65M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 217.11 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.68 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3418.41% |
| Net Margin (Trailing 12 Months) | -3407.98% |
| Return on Equity (Trailing 12 Months) | -187.59% |
| Return on Assets (Trailing 12 Months) | -167.21% |
| Current Ratio (Most Recent Fiscal Quarter) | 16.42 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.89 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.64 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 13.30M |
| Free Float | 10.11M |
| Market Capitalization | $35.39M |
| Average Volume (Last 20 Days) | 0.43M |
| Beta (Past 60 Months) | 4.24 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 24.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |